Nurix Therapeutics (NRIX) Return on Sales (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Return on Sales data on file, last reported at 0.14% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.14%, down 11.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 0.07% (down 3.0% YoY), and the FY2025 annual result was 0.03%, changed 0.0% from the prior year.
• Return on Sales slipped to 0.14% in Q1 2026 per NRIX's latest filing, from 0.06% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q2 2023 and troughed at 0.14% in Q1 2026.
• A 5-year average of 0.05% and a median of 0.04% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2023 and 2026: Return on Sales grew 4 bps in 2023, then declined 11 bps in 2026.
• A 5-year view of Return on Sales shows it stood at 0.07% in 2022, then jumped by 60 bps to 0.03% in 2023, then tumbled by 59 bps to 0.04% in 2024, then slumped by 31 bps to 0.06% in 2025, then slumped by 142 bps to 0.14% in 2026.
• Business Quant data shows NRIX's Return on Sales at 0.14% in Q1 2026, 0.06% in Q4 2025, and 0.11% in Q3 2025.